-+ 0.00%
-+ 0.00%
-+ 0.00%

Nurix Therapeutics Says FDA Clears IND for IRAK4 Degrader GS-6791/NX-0479, Enabling Initiation Of Phase 1 trial, Which Is Expected To Begin in Q2 2025

Benzinga·04/17/2025 11:04:47
Listen to the news

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025

GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis

Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing the total amount received under the 2019 collaboration agreement to $135 million

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the IRAK4 degrader program as well as potential future royalties and retains an option to co-develop and co-detail in the United States with the parties splitting U.S. profits and losses

SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared the IND for the IRAK4 degrader GS-6791/NX-0479, enabling the initiation of a Phase 1 trial, which is anticipated to begin in Q2 2025.